About this trial
An open label pilot study in mild to moderate AD patients to assess the effects of treatment with ECHS AD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices. They will treat themselves at home three times a day for 15 minutes over 120 days. Primary end points are the The Alzheimer's Disease Assessment Scale-Cognitive Subscale and the Mini-Mental State Exam. Participants will be followed-up for 9 months post-treatment.
Eligibility criteria
Qualifiers
Age ≥ 50 years
Patients diagnosed with mild to moderate Alzheimer's Dementia defi
At least an eighth grade of educational achievement
If female, post-menopausal.
Disqualifiers
The patient lacks capacity to consent to study participation and no surrogate is available to provide consent
History of epileptic seizures or epilepsy
Currently taking medication that lowers the seizure threshold
Presence of depression, bipolar disorder, a psychotic disorder, or any other neurological or psychiatric condition (whether now or in the past), which the Investigator finds as interfering with the study
Trial design
Treatments tested in this trial
- ECHS AD Device
Treatment groups
Sponsors and collaborators
Herrick Medical LLC
Lead sponsor
Hackensack Meridian Health
Collaborator